PFF Help Center(844) 825-5733

To navigate the following site navigation expect to utilize the tab key to move through items sequentially. The spacebar or enter keys can be utilized to interact with items that open sub-navigation.

Drug

ABBV-142

Status:

Phase 2

Condition:

Idiopathic Pulmonary Fibrosis

Intervention Type:

Subcutaneous (SC) Injection

Funder Type:

Industry

Drug Details

ABBV-142 is an investigational lysophosphatidic acid receptor 1 (LPAR1) antagonist antibody that blocks the LPAR1 pathway, which contributes to lung inflammation and fibrosis.

Study Purpose

This is a randomized, double-blind, placebo-controlled, multi-center study that evaluates the safety and efficacy of ABBV-142 compared to placebo.